AZX 1101

Drug Profile

AZX 1101

Alternative Names: AZX1101

Latest Information Update: 22 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AzurRx BioPharma
  • Class Antibacterials; Enzymes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Nosocomial infections

Most Recent Events

  • 20 Dec 2017 AzurRx has patent protection for AZX 1101 in USA
  • 01 Dec 2016 Preclinical trials in Nosocomial infections (Prevention) in France (PO)
  • 01 Dec 2016 AzurRx Biopharma announces intention to submit IND application in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top